ObjectivesThe objectives were to evaluate the pharmacokinetics (PK) of subcutaneous (SC) and intravenous (IV) dolasetron and the pharmacodynamics (PD) of SC dolasetron in healthy cats.MethodsFive cats with unremarkable complete blood count, serum …
ObjectivesThe objectives were to evaluate the pharmacokinetics (PK) of subcutaneous (SC) and intravenous (IV) dolasetron and the pharmacodynamics (PD) of SC dolasetron in healthy cats.MethodsFive cats with unremarkable complete blood count, serum …